H.C. Wainwright reiterates Buy rating on Aardvark Therapeutics stock

Published 23/09/2025, 12:24
H.C. Wainwright reiterates Buy rating on Aardvark Therapeutics stock

Investing.com - H.C. Wainwright has reiterated its Buy rating and $40.00 price target on Aardvark Therapeutics Inc (NASDAQ:AARD), following Pfizer’s acquisition announcement of Metsera. The stock, currently trading at $11.23, has shown strong momentum with a 9.45% gain over the past week. According to InvestingPro data, analyst targets range from $19 to $50, suggesting significant upside potential.

On Monday, Pfizer announced a deal to acquire Metsera for an initial $4.9 billion in cash, with potential additional payments of $2.4 billion tied to milestone achievements.

The acquisition gives Pfizer access to Metsera’s pipeline of injectable and oral drug candidates, including MET-097i, a Phase 2b injectable GLP-1 receptor agonist that could support monthly dosing.

Metsera’s clinical pipeline also includes a monthly injectable amylin analog with potential for combination with MET-097i, and an oral GLP-1 designed for enhanced weight loss compared to small molecules.

H.C. Wainwright noted that the substantial premium of over 50% paid for Metsera enhances Aardvark’s appeal in the obesity treatment market, supporting the firm’s maintained Buy rating and 12-month price target. InvestingPro analysis shows AARD maintains a GOOD financial health score, with a robust current ratio of 14.04 and more cash than debt on its balance sheet. Unlock 8 additional ProTips and comprehensive valuation metrics with an InvestingPro subscription.

In other recent news, Aardvark Therapeutics announced promising results from a preclinical study of its investigational drug ARD-201, which showed a 19% body weight reduction in diet-induced obese mice after 30 days of treatment. The study also indicated that ARD-201 helped maintain weight loss when combined with low-dose tirzepatide. Meanwhile, Cantor Fitzgerald reiterated its Overweight rating on Aardvark Therapeutics, maintaining a $50.00 price target, citing the company’s market capitalization and potential success in its Phase 3 study. RBC Capital, however, lowered its price target for Aardvark to $19.00 from $20.00, pointing to delays in the company’s clinical plans, including the postponed start of a Phase III trial for its ’101 drug in Prader-Willi syndrome to the third quarter of 2026. Additionally, H.C. Wainwright initiated coverage on Aardvark with a Buy rating and a $40.00 price target, noting the company’s innovative approach in treating obesity and hyperphagic conditions. These developments reflect a mix of optimism and caution among analysts regarding Aardvark’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.